Fadrozole (hydrochloride hemihydrate)

Fadrozole hydrochloride hemihydrate is an orally active, potent, selective and nonsteroidal aromatase inhibitor, with an IC50 of 6.4 nM. Fadrozole hydrochloride hemihydrate inhibits the production of estrogen and progesterone, with IC50 values of 0.03 and 120 μM. Fadrozole hydrochloride hemihydrate shows prevention of spontaneous tumours. Fadrozole hydrochloride hemihydrate can be used for the research of estrogen-dependent disease and cancer[1][2][3].

Product Specifications

CAS Number

[176702-70-8]

Product Name Alternative

CGS 16949A (hemihydrate) ; (Rac) -FAD286 (hydrochloride hemihydrate)

UNSPSC

12352005

Hazard Statement

H301+H311+H331, H315, H319

Target

Cytochrome P450

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/fadrozole-hydrochloride-hemihydrate.html

Purity

99.59

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

N#CC1=CC=C(C=C1)C2CCCC3=CN=CN23.[H]Cl.[H]O[H].[1/2]

Molecular Formula

C14H13N3.ClH.1/2H2O

Molecular Weight

268.74

Precautions

H301+H311+H331, H315, H319

References & Citations

[1]Browne LJ, et al. Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease. J Med Chem. 1991 Feb;34 (2) :725-36.|[2]Gunson DE, et al. Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor. Br J Cancer. 1995 Jul;72 (1) :72-5.|[3]Morales-Montor J, et al. Inhibition of p-450 aromatase prevents feminisation and induces protection during cysticercosis. Int J Parasitol. 2002 Oct;32 (11) :1379-87.